| Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma A Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ... Journal of clinical oncology 31 (5), 616-622, 2013 | 926 | 2013 |
| Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte–associated antigen 4 monoclonal antibody CP-675,206 A Ribas, LH Camacho, G Lopez-Berestein, D Pavlov, CA Bulanhagui, ... Journal of clinical oncology 23 (35), 8968-8977, 2005 | 735 | 2005 |
| Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised … NY Lee, RL Ferris, A Psyrri, RI Haddad, M Tahara, J Bourhis, K Harrington, ... The Lancet Oncology 22 (4), 450-462, 2021 | 466 | 2021 |
| Phase I/II trial of tremelimumab in patients with metastatic melanoma LH Camacho, S Antonia, J Sosman, JM Kirkwood, TF Gajewski, ... Journal of clinical oncology 27 (7), 1075-1081, 2009 | 370 | 2009 |
| Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial BI Rini, B Melichar, T Ueda, V Grünwald, MN Fishman, JA Arranz, AH Bair, ... The lancet oncology 14 (12), 1233-1242, 2013 | 268 | 2013 |
| Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial TH Brümmendorf, JE Cortes, CA de Souza, F Guilhot, L Duvillié, D Pavlov, ... British journal of haematology 168 (1), 69-81, 2015 | 237 | 2015 |
| Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma A Ribas, A Hauschild, R Kefford, CJ Punt, JB Haanen, M Marmol, C Garbe, ... Journal of Clinical Oncology 26 (15_suppl), LBA9011-LBA9011, 2008 | 205 | 2008 |
| Comorbidity as a predictor of stage of illness for patients with breast cancer ST Fleming, HG Pursley, B Newman, D Pavlov, K Chen Medical care 43 (2), 132-140, 2005 | 198 | 2005 |
| Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia C Gambacorti‐Passerini, JE Cortes, JH Lipton, A Dmoszynska, RS Wong, ... American journal of hematology 89 (10), 947-953, 2014 | 123 | 2014 |
| Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinib JE Cortes, H Jean Khoury, H Kantarjian, TH Brümmendorf, MJ Mauro, ... American journal of hematology 91 (6), 606-616, 2016 | 99 | 2016 |
| Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma E Wang, D Kang, KS Bae, MA Marshall, D Pavlov, K Parivar The Journal of Clinical Pharmacology 54 (10), 1108-1116, 2014 | 52 | 2014 |
| 910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally … EE Cohen, RL Ferris, A Psyrri, R Haddad, M Tahara, J Bourhis, ... Annals of Oncology 31, S658, 2020 | 50 | 2020 |
| Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma A Ribas, S Antonia, J Sosman, JM Kirkwood, B Redman, TF Gajewski, ... Journal of Clinical Oncology 25 (18_suppl), 3000-3000, 2007 | 47 | 2007 |
| The development and validation of a comorbidity index for prostate cancer among Black men ST Fleming, KA Pearce, K McDavid, D Pavlov Journal of clinical epidemiology 56 (11), 1064-1075, 2003 | 35 | 2003 |
| Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma A Ribas, VA Bozon, G Lopez-Berestein, D Pavlov, JM Reuben, CA Parker, ... Journal of Clinical Oncology 23 (16_suppl), 7524-7524, 2005 | 33 | 2005 |
| Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study TH Brümmendorf, HM Kantarjian, C Gambacorti-Passerini, F Guilhot, ... Blood 120 (21), 69, 2012 | 31 | 2012 |
| Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study J Gomez-Navarro, S Antonia, J Sosman, JM Kirkwood, B Redman, ... Journal of Clinical Oncology 25 (18_suppl), 8524-8524, 2007 | 26 | 2007 |
| Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma J Gomez-Navarro, A Sharma, V Bozon, C Bulanhagui, D Pavlov, S Eck, ... Journal of Clinical Oncology 24 (18_suppl), 8032-8032, 2006 | 23 | 2006 |
| Comorbidities and the risk of late‐stage prostate cancer ST Fleming, K McDavid, K Pearce, D Pavlov The scientific world journal 6 (1), 2460-2470, 2006 | 20 | 2006 |
| Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival CA Bulanhagui, A Ribas, D Pavlov, V Bozon, A Sharma, ... Journal of Clinical Oncology 24 (18_suppl), 8036-8036, 2006 | 19 | 2006 |
